The rapid take-up puts Camzyos on course to achieve blockbuster ... while BMS has said it believes the drug could reach $4 billion if its label is extended to include non-obstructive HCM, for ...

Camzyos (mavacamten) was approved by the FDA in April to treat obstructive hypertrophic ... The FDA is due to decide on the new label by 16 June next year. "We see a lot of potential to drive ...

rival therapy Camzyos, which is trailing initial projections, the analyst projected a different outlook for aficamten, arguing that it will become the “option of choice” with a superior label ...

Camzyos (mavacamten), a first-in-class heart disease drug, was approved by the FDA on April 28, 2022 to treat symptomatic obstructive hypertrophic cardiomyopathy (HCM), a genetic condition that causes ...

BMY is banking on new drugs to offset generic competition for older drugs. However, this might not be enough as the outlook ...